Biomarkers Improving Genetic and Metastatic Disease Prediction in Paraganglioma: Insights From a Prospective Study
Authors' conclusion
Circulating miR-483-5p, plasma succinate, TERT promoter methylation, and SDHB immunostaining are valuable for PPGL risk stratification. Combining biomarkers with clinical data provides excellent diagnostic accuracy for metastatic patients (AUC-ROC 0.97, 95%CI 0.93-1).
Study context
- Population
- Consecutive patients with PPGL, 16 referral centers, November 2015–March 2019 (COMETE-TACTIC)
- Participants
- 231 consecutive patients
- Comparison
- Genomic, metabolomic and histopathological biomarkers for predicting metastatic and genetic status
- Outcome
- Prediction of SDHx status and metastatic status
Methodological detailsprospective, multicentre, consecutive patients
- Prospective
- Multicentre
- Consecutive patients
Performance
As reported in the abstract
| Test or model | AUC (95% CI) | AUC for SDHx status (95% CI) | AUC for metastatic potential (95% CI) | Sensitivity | Specificity |
|---|---|---|---|---|---|
| Plasma succinate | 0.82 (0.70-0.93) | — not stated in the abstract | — not stated in the abstract | 65% | 92% |
| miR-483-5p | 0.64 (0.52-0.77) | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| TERT promoter methylation | 0.75 (0.65-0.85) | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract | — not stated in the abstract |
| Biomarker combinations | — not stated in the abstract | 0.99 (0.98-1.00) | 0.93 (0.84-1) | — not stated in the abstract | — not stated in the abstract |
AUC (95% CI)
Plasma succinate0.82 (0.70-0.93)
miR-483-5p0.64 (0.52-0.77)
TERT promoter methylation0.75 (0.65-0.85)
Biomarker combinations— not stated in the abstract
AUC for SDHx status (95% CI)
Plasma succinate— not stated in the abstract
miR-483-5p— not stated in the abstract
TERT promoter methylation— not stated in the abstract
Biomarker combinations0.99 (0.98-1.00)
AUC for metastatic potential (95% CI)
Plasma succinate— not stated in the abstract
miR-483-5p— not stated in the abstract
TERT promoter methylation— not stated in the abstract
Biomarker combinations0.93 (0.84-1)
Sensitivity
Plasma succinate65%
miR-483-5p— not stated in the abstract
TERT promoter methylation— not stated in the abstract
Biomarker combinations— not stated in the abstract
Specificity
Plasma succinate92%
miR-483-5p— not stated in the abstract
TERT promoter methylation— not stated in the abstract
Biomarker combinations— not stated in the abstract
— not stated in the abstract
Further findings
Biomarkers combined with clinical data for metastatic patients
- AUC
- 0.97 (0.93-1) (95% CI)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Biomarkers Improving Genetic and Metastatic Disease Prediction in Paraganglioma: Insights From a Prospective Study. J Clin Endocrinol Metab. Published 14 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →